NCT05987956View on ClinicalTrials.gov

Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

November 8, 2025

Primary Completion Date

November 18, 2026

Study Completion Date

December 28, 2026

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Alectinib - Usual

"Usual Alectinib Chemotherapy (NDC...01)~\- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"

DRUG

Alectinib - Study

"Study Alectinib Chemotherapy (NDC...86)~\- ALECENSA - alectinib hydrochloride capsule -- 600 mg orally twice daily"

Trial Locations (1)

20853

Medicine Invention Design, Inc. - IORG0007849, Rockville

All Listed Sponsors
collaborator

UnitedHealthcare

OTHER

lead

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

INDUSTRY